Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00785213 · ClinicalTrials.gov registry record · Phase 1
Drug-Drug Interaction Study Between Quinine Sulfate and Rosiglitazone
A Phase 1 study, sponsored by Mutual Pharmaceutical Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT00785213: Completed Phase 1 study, sponsored by Mutual Pharmaceutical Company.
NCT00785213 is a Phase 1 study that has completed, run by Mutual Pharmaceutical Company. The registered enrollment target is 23 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (62% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00785213, a Phase 1 study, has completed, sponsored by Mutual Pharmaceutical Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
Rosiglitazone is predominantly metabolized by cytochrome P450 (CYP) 2C8. Quinine sulfate is an inhibitor of CYP 2C8. This study will evaluate the effect of multiple doses of quinine sulfate at steady-state on the pharmacokinetics of single-dose rosiglitazone in healthy adult subjects.
Primary Outcome
The maximum or peak concentration that rosiglitazone reaches in the plasma.
Interventions
- DRUG Rosiglitazone 4 mg Tablets
- DRUG Quinine Sulfate 324 mg Capsules
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2008-09 |
| Est. Completion | 2008-10 |
| Phase | Phase 1 |
What the finished NCT00785213 record still lists
NCT00785213 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (62% lower).
The record links to 0 conditions, and to 2 interventions - of which Rosiglitazone 4 mg Tablets is the first listed.
NCT00785213 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00785213 about?
NCT00785213 is a clinical study titled "Drug-Drug Interaction Study Between Quinine Sulfate and Rosiglitazone". Rosiglitazone is predominantly metabolized by cytochrome P450 (CYP) 2C8. Quinine sulfate is an inhibitor of CYP 2C8. This study will evaluate the effect of multiple doses of quinine sulfate at steady-state on the pharmacokinetics of single-dose rosiglitazone in healthy adult subjects.
What is the current status of trial NCT00785213?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2008-09. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00785213?
The interventions under investigation include: Rosiglitazone 4 mg Tablets (DRUG), Quinine Sulfate 324 mg Capsules (DRUG).
Who is sponsoring clinical trial NCT00785213?
This trial is sponsored by Mutual Pharmaceutical Company, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00785213's enrollment target sits among peer trials
23 1596th of 2000 higher than 400 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia